Postoperative radiotherapy in the management of vulvar cancer

##plugins.themes.academic_pro.article.sidebar##

Published Dec 1, 2024
https://doi.org/10.62438/tunismed.v102i12.5236
Download
pdf
Vol. 102 No. 12 (2024): Tunis Med dec 2024

##plugins.themes.academic_pro.article.main##

Souha Massoudi
Department of radiation oncology, Farhat Hached University Hospital of Sousse, Tunisia
Sabrine Tbessi
Department of radiation oncology, Farhat Hached University Hospital of Sousse, Tunisia
Sonia Zaied
Department of radiation oncology, Farhat Hached University Hospital of Sousse, Tunisia
Samia Kanoun
Department of radiation oncology, Farhat Hached University Hospital of Sousse, Tunisia
Nadia Bouzid
Department of radiation oncology, Farhat Hached University Hospital of Sousse, Tunisia
Sameh Tebra
Department of radiation oncology, Farhat Hached University Hospital of Sousse, Tunisia

Abstract

background: Vulvar cancer is a rare tumor whose prognosis depends on early treatment.


Aim: The study aimed to evaluate the role of adjuvant radiotherapy (RT) in the treatment of vulvar cancer and to identify the prognostic factors influencing the tumor evolution.


Methods: descriptive and analytical study included 38 patients treated by adjuvant RT, during the period from 1995 to 2020, for vulvar cancer in the oncological radiotherapy department of Farhat Hached University Hospital in Sousse.


Results: All patients underwent adjuvant RT. After a median follow-up of 55 months, 24 patients are in complete remission (63.2%). We noted local and regional recurrences in 23.7% and 13.2% of cases. Two patients had distant bone progression. Overall survival (OS) was 72% at five years and 51% at ten years. The 5-year local (SSRL) and regional (SSRR) recurrence-free survival was 76% and 87%, respectively. In univariate analysis, the factors associated with OS were the size of the tumor (p=0.02), the quality of excision (p=0.000) and age (p=0.04). The quality of excision (p = 0.001) and inguinal dissection (p = 0.05) was associated with SSRL. In addition, those influencing the SSRR were lymph node invasion and the quality of excision.


Conclusion: vulvar cancer requires early diagnosis in order to consider less invasive treatment with advances in RT techniques.

Keywords:

vulvar cancer, adjuvant radiotherapy, chemotherapy, surgery, prognostic factors

##plugins.themes.academic_pro.article.details##

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

References

  1. Bucchi L, Pizzato M, Rosso S, Ferretti S. New Insights into the Epidemiology of Vulvar Cancer: Systematic Literature Review for an Update of Incidence and Risk Factors. Cancers. 13 janv 2022;14(2):389.
  2. Hampl M, Deckers-Figiel S, Hampl JA, Rein D, Bender HG. New aspects of vulvar cancer: Changes in localization and age of onset. Gynecol Oncol. juin 2008;109(3):340‑5.
  3. Koh WJ, Greer BE, Abu-Rustum NR, Campos SM, Cho KR, Chon HS, et al. Vulvar Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. janv 2017;15(1):92‑120.
  4. Homesley HD, Bundy BN, Sedlis A, Adcock L. Radiation therapy versus pelvic node resection for carcinoma of the vulva with positive groin nodes. Obstet Gynecol. déc 1986;68(6):733‑40.
  5. Kunos C, Simpkins F, Gibbons H, Tian C, Homesley H. Radiation Therapy Compared With Pelvic Node Resection for Node-Positive Vulvar Cancer: A Randomized Controlled Trial. Obstet Gynecol. sept 2009;114(3):537‑46.
  6. Mahner S, Jueckstock J, Hilpert F, Neuser P, Harter P, de Gregorio N, et al. Adjuvant Therapy in Lymph Node–Positive Vulvar Cancer: The AGO-CaRE-1 Study. JNCI J Natl Cancer Inst [Internet]. mars 2015 [cité 20 sept 2022];107(3). Disponible sur: https://academic.oup.com/jnci/article-lookup/doi/10.1093/jnci/dju426
  7. Fons G, Groenen SMA, Oonk MHM, Ansink AC, van der Zee AGJ, Burger MPM, et al. Adjuvant radiotherapy in patients with vulvar cancer and one intra capsular lymph node metastasis is not beneficial. Gynecol Oncol. août 2009;114(2):343‑5.
  8. van der Velden J, Pleunis N, Barlow E, Zijlmans H, de Hullu J, Hacker NF, et al. Radiotherapy is not indicated in patients with vulvar squamous cell carcinoma and only one occult intracapsular groin node metastasis. Gynecol Oncol. janv 2021;160(1):128‑33.
  9. Parthasarathy A, Cheung MK, Osann K, Husain A, Teng NN, Berek JS, et al. The benefit of adjuvant radiation therapy in single-node-positive squamous cell vulvar carcinoma. Gynecol Oncol. déc 2006;103(3):1095‑9.
  10. Oonk MHM, Slomovitz B, Baldwin PJW, van Doorn HC, van der Velden J, de Hullu JA, et al. Radiotherapy Versus Inguinofemoral Lymphadenectomy as Treatment for Vulvar Cancer Patients With Micrometastases in the Sentinel Node: Results of GROINSS-V II. J Clin Oncol. 10 nov 2021;39(32):3623‑32.
  11. Gien LT, Slomovitz BM, Leitao MM, Van Der Zee A, Creutzberg CL, Reyners AKL, et al. Trial in progress: Phase II activity trial of high-dose radiation and chemosensitization in patients with macrometastatic lymph node spread after sentinel node biopsy in vulvar cancer: Groningen International Study on Sentinel Nodes in Vulvar Cancer III (GROINSS-V III/NRG-GY024). J Clin Oncol. 1 juin 2022;40(16_suppl):TPS5624‑TPS5624.
  12. Ignatov T, Eggemann H, Burger E, Costa SD, Ignatov A. Adjuvant radiotherapy for vulvar cancer with close or positive surgical margins. J Cancer Res Clin Oncol. févr 2016;142(2):489‑95.
  13. Viswanathan AN, Pinto AP, Schultz D, Berkowitz R, Crum CP. Relationship of margin status and radiation dose to recurrence in post-operative vulvar carcinoma. Gynecol Oncol. sept 2013;130(3):545‑9.
  14. Chapman BV, Gill BS, Viswanathan AN, Balasubramani GK, Sukumvanich P, Beriwal S. Adjuvant Radiation Therapy for Margin-Positive Vulvar Squamous Cell Carcinoma: Defining the Ideal Dose-Response Using the National Cancer Data Base. Int J Radiat Oncol. janv 2017;97(1):107‑17.
  15. Mazumder K, Elangovan A, Rai B, Suri V, Jain V, Kalra J, et al. Conventional radiotherapy and intensity-modulated radiotherapy in carcinoma vulva: An experience from a tertiary medical center of India. South Asian J Cancer. janv 2019;08(01):41‑3.
  16. Khosla D, Patel F, Shukla A, Rai B, Oinam A, Sharma S. Dosimetric evaluation and clinical outcome in post-operative patients of carcinoma vulva treated with intensity-modulated radiotherapy. Indian J Cancer. 2015;52(4):670.
  17. Bloemers MCWM, Portelance L, Ruo R, Parker W, Souhami L. A dosimetric evaluation of dose escalation for the radical treatment of locally advanced vulvar cancer by intensity-modulated radiation therapy. Med Dosim. sept 2012;37(3):310‑3.
  18. Portelance L, Chao KSC, Grigsby PW, Bennet H, Low D. Intensity-modulated radiation therapy (IMRT) reduces small bowel, rectum, and bladder doses in patients with cervical cancer receiving pelvic and para-aortic irradiation. Int J Radiat Oncol. sept 2001;51(1):261‑6.
  19. Roeske JC, Lujan A, Rotmensch J, Waggoner SE, Yamada D, Mundt AJ. Intensity-modulated whole pelvic radiation therapy in patients with gynecologic malignancies. Int J Radiat Oncol. déc 2000;48(5):1613‑21.
  20. Beriwal S, Heron DE, Kim H, King G, Shogan J, Bahri S, et al. Intensity-modulated radiotherapy for the treatment of vulvar carcinoma: A comparative dosimetric study with early clinical outcome. Int J Radiat Oncol. avr 2006;64(5):1395‑400.
  21. Hoffman M, Greenberg S, Greenberg H, Fiorica JV, Roberts WS, LaPolla JP, et al. Interstitial radiotherapy for the treatment of advanced orrecurrent vulvar and distal vaginal malignancy. Am J Obstet Gynecol. mai 1990;162(5):1278‑82.
  22. Pohar S, Hoffstetter S, Peiffert D, Luporsi E, Pernot M. Effectiveness of brachytherapy in treating carcinoma of the vulva. Int J Radiat Oncol. juill 1995;32(5):1455‑60.
  23. Tewari K, Cappuccini F, Syed AMN, Puthawala A, DiSaia PJ, Berman ML, et al. Interstitial brachytherapy in the treatment of advanced and recurrent vulvar cancer. Am J Obstet Gynecol. juill 1999;181(1):91‑8.
  24. Castelnau-Marchand P, Escande A, Mazeron R, Bentivegna E, Cavalcanti A, Gouy S, et al. Brachytherapy as part of the conservative treatment for primary and recurrent vulvar carcinoma. Brachytherapy. mai 2017;16(3):518‑25.
  25. Mahantshetty U, Naga P, Engineer R, Sastri S, Ghadi Y, Upreti U, et al. Clinical outcome of high-dose-rate interstitial brachytherapy in vulvar cancer: A single institutional experience. Brachytherapy. janv 2017;16(1):153‑60.
  26. Yaney A, Healy E, Pan X, Martin D, Quick A. Clinical outcomes of distal vaginal and vulvar cancer treated with image-guided brachytherapy. J Contemp Brachytherapy. 2021;13(4):419‑25.
  27. Gill BS, Bernard ME, Lin JF, Balasubramani GK, Rajagopalan MS, Sukumvanich P, et al. Impact of adjuvant chemotherapy with radiation for node-positive vulvar cancer: A National Cancer Data Base (NCDB) analysis. Gynecol Oncol. juin 2015;137(3):365‑72.
  28. Rydzewski NR, Kanis MJ, Donnelly ED, Lurain JR, Strauss JB. Role of adjuvant external beam radiotherapy and chemotherapy in one versus two or more node-positive vulvar cancer: A National Cancer Database study. Radiother Oncol. déc 2018;129(3):534‑9.
  29. Li JY, Arkfeld CK, Tymon-Rosario J, Webster E, Schwartz P, Damast S, et al. An evaluation of prognostic factors, oncologic outcomes, and management for primary and recurrent squamous cell carcinoma of the vulva. J Gynecol Oncol. 2022;33(2):e13.